인벤티바(IVA) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

IVA

Inventiva ADR

7월 27일 4:00 PM ET (한국 7/28 05:00)

$4.60

+0.14 ▲ +3.14%

🌙 7월 27일 6:51 PM ET (한국 7/28 07:51)

$4.50

-0.10 ▼ -2.17%

인벤티바(IVA) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$1.1B

스몰캡

P/E

배당수익률

없음

52주 위치

34%

저점 +61% · 고점 -42%

애널리스트

적극 매수

C+

Fundamental health

vs. 초고성장주 소형주· based on 2 axes

수익성

산출 불가 (적자)

성장

Top 58%

밸류에이션

데이터 부족

재무 안정

Top 45%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-2.84	Insider Own ⓘ	5.53%	Shs Outstand ⓘ	236.2M	Perf Week ⓘ	4.19%
Market Cap ⓘ	1.09B	Forward P/E ⓘ	-	EPS next Y ⓘ	-13.73%	Insider Trans ⓘ	-	Shs Float ⓘ	223.2M	Perf Month ⓘ	31.43%
Enterprise Value ⓘ	1.04B	PEG ⓘ	-	EPS next Q ⓘ	-0.37	Inst Own ⓘ	17.1%	Short Float ⓘ	0.8%	Perf Quarter ⓘ	-10.68%
Income ⓘ	-0.40B	P/S ⓘ	221.78	EPS this Y ⓘ	64.99%	Inst Trans ⓘ	3.18%	Short Ratio ⓘ	1.99	Perf Half Y ⓘ	-35.66%
Sales ⓘ	0.00B	P/B ⓘ	-	EPS next 5Y ⓘ	48.54%	ROA ⓘ	-192.65%	Short Interest ⓘ	1.79M	Perf YTD ⓘ	-1.08%
Book/sh ⓘ	-0.18	P/C ⓘ	9.32	EPS past 3/5Y ⓘ	-15.85% -13.59%	ROE ⓘ	-	52W High ⓘ	-42.37% ($7.98)	Perf Year ⓘ	45.27%
Cash/sh ⓘ	0.49	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-26.61% 64.18%	ROIC ⓘ	-	52W Low ⓘ	61.2% ($2.85)	Perf 3Y ⓘ	19.17%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	14.8%	Gross Margin ⓘ	33.27%	Volatility(W/M) ⓘ	5.09% 6.89%	Perf 5Y ⓘ	-66.71%
Dividend TTM ⓘ	-	EV/Sales ⓘ	212.22	Sales Y/Y TTM ⓘ	-50.8%	Oper. Margin ⓘ	-3159.89%	ATR (14) ⓘ	0.26	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	3.15	EPS Q/Q ⓘ	-	Profit Margin ⓘ	-8165.65%	RSI (14) ⓘ	58.74	Recom ⓘ	1.08
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	3.15	Sales Q/Q ⓘ	-	SMA20 ⓘ	7.07% ($4.3)	Beta ⓘ	0.69	Target Price ⓘ	$15.6
Payout ⓘ	-	Debt/Eq ⓘ	-	Earnings ⓘ	2026/7/29	SMA50 ⓘ	6.83% ($4.31)	Rel Volume ⓘ	0.78	Prev Close ⓘ	$4.46
Employees ⓘ	77	LT Debt/Eq ⓘ	-	EPS/Sales Surpr. ⓘ	-82.55% -70.33%	SMA200 ⓘ	-9.39% ($5.08)	Avg Volume(3M) ⓘ	0.90M	Price ⓘ	$4.6
IPO ⓘ	2020/7/10	Option/Short ⓘ	Yes/Yes			Trades ⓘ	4881	Volume ⓘ	704,584	Change ⓘ	3.14%

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Inventiva ADR (IVA) Investment Analysis

What kind of company is Inventiva ADR?

인벤티바(IVA) 초고성장주

Healthcare · Biotechnology

Healthcare Stocks

🧬 Inventiva is a clinical-stage biotech company developing treatments for metabolic and fibrotic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, lanifibranor—an oral pan-PPAR (peroxisome proliferator-activated receptor) agonist that activates three receptor subtypes simultaneously—is being evaluated in a global Phase 3 clinical trial and features a differentiated mechanism of action that simultaneously targets anti-fibrosis, anti-inflammation, and metabolic improvement.

Learn more about Inventiva ADR →

Market Cap

$1.1B

Approx. KRW 1.5 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank2583

Employees77people

IPO2020/07/10

Current Price$4.60 ≈ 6,302원

NASD · France

Key Events

⏰ Upcoming events

🔔 Earnings release D-1

7월 29일 (수) · 장 마감 후

예상 EPS $-0.37

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 3월 30일 (월) · 장 마감 후 EPS -82.5% 매출 -70.3%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-3159.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-8165.6%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

33.3%

✓ 부진

My positionBottom 25%

Low range Average High range

Biotechnology 소형주 Median 84.9% · Bottom 22%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROA

Annual earnings relative to total company assets

-192.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Current Ratio

Liquid assets available to cover liabilities due within a year

3.15

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

3.15

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$15.60

현재가 대비 +239.1%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

-13.7%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+48.5%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-82.5%

평균 서프라이즈

2026.03.30

하회

-82.5%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+65.0%

양호

My positionMid-range

Low range Average High range

초고성장주 소형주 Median 51.6% · Top 42%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

-13.7%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 소형주 Median 33.7% · Bottom tier

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+48.5%

양호

My positionMid-range

Low range Average High range

초고성장주 소형주 Median 40.0% · Top 40%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

-15.8%

평균

My positionMid-range

Low range Average High range

초고성장주 소형주 Median 6.9% · Bottom 30%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

-13.6%

평균

My positionMid-range

Low range Average High range

초고성장주 소형주 Median 7.0% · Bottom 26%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+64.2%

우수

My positionTop 25%

Low range Average High range

초고성장주 소형주 Median 32.4% · Top 21%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -135%p below the market

IVA -66.7% · S&P 500 +68.4%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-135.1%p

Significantly behind the market

vs Health Care (XLV)

-91.2%p

Significantly behind the sector average

1-year basis

vs S&P 500

+29.3%p

ahead of the market

vs Health Care (XLV)

+25.6%p

ahead of the sector average

Rank among peers

5-year return Lower-Mid (lower 43%) Based on 123 peers

1-year return Upper-Mid (50%) Based on 154 peers

Current position within 52-week range

Low (-61.2%p) High (-42.4%p)

Current price is 61.2% above the 52-week low and 42.4% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-50.3%

Annualized volatility

62.3%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢

Current diagnosis · 2026-07-27

Uptrend zone

Current price $4.60 above the midline ($4.30). Normal upward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢

Current diagnosis · 2026-07-27

Bullish momentum holding

MACD 0.112 > Signal 0.072 in positive zone + Hist positive (+0.040). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 58.7 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 74.1.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry

Pricey on Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🧾 Vs. Sales Pricey

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

221.78x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology 소형주 median 14.61x · Bottom 11% — expensive within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$15.60 vs. current price +239.1%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership flow is positive

Institutional net buying +3.2% · Short interest light 0.8% · Short interest up +0.5pp over last 89d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

+3.2%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 17.1%

Retail-led

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 5.5%

Meaningful insider stake

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 77.4%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

0.8%

Low — limited short-side pressure

Healthcare 소형주 Median 11.2%

Past 89 days 📈 +0.5%p increase

Short interest days to cover

2.0 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 236.2M주

Float (tradable shares) 223.2M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 89 days.

ETFs holding IVA

ETFs with the highest weightings · 3 total shown

SURI

Simplify Propel Opportunities ETF

1.82%

$77M

ISCF

iShares International Small-Cap Equity Factor ETF

0.01%

$649M

GTPE

Goldman Sachs MSCI World Private Equity Return Tracker ETF

0.00%

$30M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
IVA This Stock	$1.1B	-	-	-	-	+3.1%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

Derivative ETFs for IVA

Leveraged, inverse, and covered call ETFs based on the underlying asset

5 derivative ETFs based on IVA (Covered Call 5)

These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.

ℹ️ What is a Derivative ETF?

These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.

💰 Covered Call & Options 5 A strategy that generates monthly dividend income through covered calls